Erlotinib

Generic Name: Erlotinib

Brand Names: Tarceva

Drug Type: Small Molecule

Chemical Formula: C_₂₂H_₂₃N_₃O_₄

CAS Number: 183321-74-6

Unique Ingredient Identifier: J4T82NDH7E

Background: Erlotinib is an inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase that is used in the treatment of non-small cell lung cancer, pancreatic cancer and several other types of cancer. It is typically marketed under the trade name Tarceva. Erlotinib binds to the epidermal growth factor receptor (EGFR) tyrosine kinase in a reversible fashion at the adenosine triphosphate (ATP) binding site of the receptor. Recent studies demonstrate that erlotinib is also a potent inhibitor of JAK2V617F, which is a mutant form of tyrosine kinase JAK2 found in most patients with polycythemia vera (PV) and a substantial proportion of patients with idiopathic myelofibrosis or essential thrombocythemia. This finding introduces the potential use of erlotinib in the treatment of JAK2V617F-positive PV and other myeloproliferative disorders.

Indication: Erlotinib is indicated for:

The safety and efficacy of erlotinib have not been established for patients with NSCLC whose tumors show other EGFR mutations. Additionally it is not recommended for use in combination with platinum-based chemotherapy.

Associated Conditions: Locally Advanced Pancreatic Cancer (LAPC), Metastatic Non-Small Cell Lung Cancer, Pancreatic Metastatic Cancer, Unresectable Pancreatic Cancer

Associated Therapies: -

Clinical Trials

Safety Study of Radiotherapy and Concurrent Erlotinib (Tarceva®) for Brain Metastases From a Non-Small Cell Lung Cancer

Phase 1

Completed

Conditions: Non-Small Cell Lung Cancer
Brain Metastases

Interventions: Drug: erlotinib

First Posted Date: 2007-09-28

Last Posted Date: 2008-05-29

Lead Sponsor: Amsterdam UMC, location VUmc

Target Recruit Count: 11

Registration Number: NCT00536861

Locations: 🇳🇱
VU University Medical Center, Amsterdam, Netherlands

Erlotinib in Combination With Docetaxel in Advanced Hepatocellular and Biliary Tract Carcinomas

Phase 2

Terminated

Conditions: Hepatocellular Carcinoma

Interventions: Drug: Erlotinib
Drug: Docetaxel

First Posted Date: 2007-09-20

Last Posted Date: 2016-02-12

Lead Sponsor: Gabi Chiorean, MD

Target Recruit Count: 25

Registration Number: NCT00532441

Locations: 🇺🇸
Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States
🇺🇸
Rush-Presbyterian St. Luke's Medical Center, Chicago, Illinois, United States
🇺🇸
Helen F. Graham Cancer Center, Newark, Delaware, United States

and more 9 locations

A Study of Tarceva (Erlotinib) in Combination With Avastin (Bevacizumab) in Patients With Advanced Non-Small Cell Lung Cancer.

Phase 2

Completed

Conditions: Non-Small Cell Lung Cancer

Interventions: Drug: Bevacizumab
Drug: Erlotinib
Drug: Standard platinum-based chemotherapy

First Posted Date: 2007-09-19

Last Posted Date: 2014-11-11

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 124

Registration Number: NCT00531960

Clinical Trial of the Safety and Effectiveness of CHR-2797 With Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer

Phase 1

Terminated

Conditions: Carcinoma, Non-Small-Cell Lung

First Posted Date: 2007-08-30

Last Posted Date: 2012-06-28

Lead Sponsor: Chroma Therapeutics

Target Recruit Count: 2

Registration Number: NCT00522938

Locations: 🇺🇸
Medical Oncology Care Associates, Orange, California, United States
🇺🇸
Tower Cancer Research Foundation, Beverly Hills, California, United States
🇺🇸
Clinworks Research Center, Charlotte, North Carolina, United States

and more 4 locations

Study of Pegylated Alfa Interferon, Sunitinib and Tarceva in Patients With Metastatic RCC

Phase 1

Terminated

Conditions: Carcinoma, Renal Cell

Interventions: Drug: Pegylated Alfa Interferon
Drug: sunitinib
Drug: erlotinib

First Posted Date: 2007-08-29

Last Posted Date: 2016-03-17

Lead Sponsor: The Methodist Hospital Research Institute

Target Recruit Count: 10

Registration Number: NCT00522249

Locations: 🇺🇸
Baylor College of Medicine - Methodist Hospital, Houston, Texas, United States

Avastin +/- Erlotinib Consolidation Chemotherapy After Carboplatin, Paclitaxel, and Avastin (CTA) Induction Therapy for Advanced Ovarian, Fallopian Tube, Primary Peritoneal Cancer & Papillary Serous or Clear Cell Mullerian Tumors

Phase 2

Completed

Conditions: Ovarian Cancer
Fallopian Tube Cancer
Primary Peritoneal Cancer
Papillary Serous Mullerian Tumor
Clear Cell Mullerian Tumor

Interventions: Drug: bevacizumab
Drug: paclitaxel
Drug: erlotinib
Drug: carboplatin

First Posted Date: 2007-08-23

Last Posted Date: 2018-07-27

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 60

Registration Number: NCT00520013

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

A Study of Tarceva (Erlotinib) and Gemcitabine in Treatment-Naive Patients With Advanced Non-Small Cell Lung Cancer.

Phase 2

Completed

Conditions: Non-Squamous Non-Small Cell Lung Cancer

Interventions: Drug: Gemcitabine
Drug: Erlotinib

First Posted Date: 2007-08-17

Last Posted Date: 2016-05-16

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 17

Registration Number: NCT00518011

Phase II Trial of Erlotinib in Advanced Pancreatic Cancer

Phase 2

Completed

Conditions: Pancreas
Cancer

Interventions: Drug: Erlotinib

First Posted Date: 2007-07-06

Last Posted Date: 2019-05-30

Lead Sponsor: University Health Network, Toronto

Target Recruit Count: 51

Registration Number: NCT00497224

Locations: 🇨🇦
CancerCare Manitoba, Winnipeg, Manitoba, Canada
🇨🇦
Tom Baker Cancer Centre, Calgary, Alberta, Canada
🇨🇦
Princess Margaret Hospital, Toronto, Ontario, Canada

and more 2 locations